Walleye Capital’s Sutro Biopharma STRO Stock Holding History

Walleye Capital’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$309K	Buy	+9,306	New	+$290K	﹤0.01%	3151
2024 Q1	–	Sell	-7,327	Closed	-$314K	–	5878
2023 Q4	$314K	Buy	+7,327	New	+$233K	﹤0.01%	3340
2023 Q1	–	Sell	-1,806	Closed	-$146K	–	4345
2022 Q4	$146K	Sell	1,806 -17,366	-91%	-$1.21M	﹤0.01%	2221
2022 Q3	$1.06M	Sell	19,172 -8,104	-30%	-$480K	0.02%	927
2022 Q2	$1.42M	Buy	27,276 +20,915	+329%	+$1.17M	0.04%	483
2022 Q1	$523K	Sell	6,361 -1,180	-16%	-$112K	0.01%	993
2021 Q4	$1.12M	Buy	+7,541	New	+$1.35M	0.03%	519
2018 Q3	$201K	Buy	+1,340	New	+$202K	0.09%	219

Other funds holding STRO

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.22B AUM 242.83% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return

OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Walleye Capital's STRO Position: Q2 2026 in Review

Walleye Capital opened a new position in Sutro Biopharma (STRO) in Q2 2026: 9,306 shares worth $309K. The stake represents ﹤0.01% of the portfolio and ranks #3151 among its holdings. This is a return to the name: Walleye Capital previously reported a position in STRO as recently as Q4 2023.

Walleye Capital first reported a position in STRO in Q3 2018 and has held it in 8 quarters since. The position peaked at $1.42M in Q2 2022. 100 funds tracked by Wall St. Rank hold STRO as of Q2 2026.

Walleye Capital held 9,306 shares of Sutro Biopharma worth $309K as of Q2 2026.
Sutro Biopharma was a new Walleye Capital position in Q2 2026.
Sutro Biopharma made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #3151 holding.
Walleye Capital first reported a position in Sutro Biopharma in Q3 2018 and has held it in 8 quarters since.
Walleye Capital's Sutro Biopharma position peaked at $1.42M in Q2 2022.
100 funds tracked by Wall St. Rank held Sutro Biopharma as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.